Table 3. Therapeutic efficacy outcomes.
| Characteristics | CR | PR | PD | Time to CR (mo) | Relapse | Time to relapse (mo) | Follow-up (mo) |
|---|---|---|---|---|---|---|---|
| ACH | 25/28 (89.3) | 2/28 (7.1) | 1/28 (3.6) | 6.7±4.0 | 9/25 (36.0) | 34.0±22.4 | 76.4±48.8 |
| EC G1 | 13/16 (81.3) | 1/16 (6.3) | 2/16 (12.5) | 5.0±2.9 | 5/13 (38.5) | 25.0±12.9 | 85.3±48.3 |
| EC G2 | 3/4 (75.0) | 0/4 (0) | 1/4 (25.0) | 4.0±0 | 3/3 (100) | 14.3±1.5 | 115.5±2.6 |
| Total | 41/48 (85.4) | 3/48 (6.3) | 4/48 (8.3) | 7.6±4.0 | 17/41 (41.5) | 28.6±20.1 | 82.6±47.2 |
Data are presented as mean±standard deviation or number (%).
ACH, atypical complex hyperplasia; CR, complete response; EC, endometrial cancer; G, grade; PD, progressive disease; PR, partial response.